Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcrip…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Trend
+18.0% vs SMA 50 · +96.5% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $323.7M $322.9M–$324.2M | — | -$0.54 | — | ±0% | Low2 |
FY2024 | $341.2M $341.1M–$341.3M | ▲ +5.4% | -$0.05 | — | ±0% | Moderate3 |
FY2025 | $431.1M $431.1M–$431.2M | ▲ +26.4% | $0.03 | — | ±20% | Moderate4 |
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcrip…

SkyWater is a U.S.-owned and U.S.-based pure play semiconductor foundry and is a DOD-accredited Trusted supplier that specializes in custom technology development services, volume manufacturing, and advanced packaging capabilities.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
SKYT◀ | $33.43 | +0.63% | $1.6B | 13.1 | +2917.9% | 2689.5% | 1500 |
| $196.50 | +0.02% | $4.8T | 40.2 | +6547.4% | 5560.3% | 1495 | |
| $284.18 | -1.18% | $4.1T | 33.2 | +642.6% | 2691.5% | 1494 | |
| $411.38 | -0.20% | $3.1T | 24.5 | +1493.2% | 3614.6% | 1477 | |
| $427.36 | -1.13% | $2.0T | 79.1 | +2387.4% | 3619.8% | 1504 | |
| $640.20 | +6.31% | $650.1B | 26.9 | +4885.1% | 2284.5% | 1534 | |
| $355.26 | -5.27% | $556.9B | 128.4 | +3433.8% | 1251.5% | 1517 | |
| Sector avg | — | -0.12% | — | 49.4 | +3186.8% | 3101.7% | 1503 |